midazolam has been researched along with Alzheimer Disease in 4 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Excerpt | Relevance | Reference |
---|---|---|
"Midazolam is a hypnotic-sedative drug with pleiotropic properties." | 1.91 | Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease. ( Chen, Y; Luan, H; Wang, P; Wu, Y, 2023) |
"Midazolam treatment decreased GM1 expression in the detergent-resistant membrane microdomains of neurons, and these effects were regulated by the gamma-aminobutyric acid-A receptor." | 1.42 | Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor. ( Arima, H; Hirate, H; Kusama, N; Sobue, K; Sugiura, T; Suzuki, K; Yamamoto, N, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Wang, P | 6 |
Luan, H | 3 |
Wu, Y | 3 |
Chen, Y | 3 |
Yamamoto, N | 1 |
Arima, H | 1 |
Sugiura, T | 1 |
Hirate, H | 1 |
Kusama, N | 1 |
Suzuki, K | 1 |
Sobue, K | 1 |
Passmore, MJ | 1 |
Sheldon, L | 1 |
Lax, S | 1 |
Wilkins-Ho, M | 1 |
Illing, M | 1 |
Kálmán, J | 1 |
Palotás, M | 1 |
Pákáski, M | 1 |
Hugyecz, M | 1 |
Janka, Z | 1 |
Palotás, A | 1 |
4 other studies available for midazolam and Alzheimer Disease
Article | Year |
---|---|
Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cellular Senescence; Cyclooxygenase 2; H | 2023 |
Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cellular Senescence; Cyclooxygenase 2; H | 2023 |
Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cellular Senescence; Cyclooxygenase 2; H | 2023 |
Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cellular Senescence; Cyclooxygenase 2; H | 2023 |
Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor.
Topics: Alzheimer Disease; Amyloid; Anesthetics, Intravenous; Animals; Cells, Cultured; G(M1) Ganglioside; M | 2015 |
Oral midazolam for dementia-related response agitation.
Topics: Administration, Oral; Aged, 80 and over; Aggression; Alzheimer Disease; Female; Humans; Hypnotics an | 2009 |
Unchanged rat brain amyloid precursor protein levels after exposure to benzodiazepines in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthesia, General; Animals; Antibodies, Monoclonal; Benz | 2006 |